Inito, established in 2015 by Aayush Rai (CEO) and Varun A Venkatesan (CTO), is a Meditech startup specializing in products that monitor fertility hormones. Its flagship product, the Fertility Monitor, provides personalized analytics on reproductive health. These items, including fertility monitors and kits, are available for purchase on e-commerce platforms such as Inito and Amazon. The innovative design of Inito’s fertility monitors and kits allows users to receive clear fertility diagnostic results on their phones within a quick 10-minute time frame.
How Does It Work?
The start-up envisions offering providing universal access to healthcare and body data for every individual. In a time when fertility issues are prevalent globally, the MedTech startup employs a blend of hardware, biotechnology, and machine learning to enhance the precision, reliability, and density of test strips. This innovation enables the measurement of multiple parameters on a single testing platform.
Inito’s testing kit includes a monitor, test strips, and access to the Inito app. The smartphone monitor from Inito accurately interprets high-density test strips, delivering personalized results based on the user’s cycle history. In contrast to standard tests that yield only “yes/no”; results, Inito provides numerical values for fertility hormones, enriching the user’s fertility experience.
Moreover, Inito captures data related to irregular cycles, identifying fertile days and offering suggestions. The startup also plans to introduce a variety of additional fertility tests and beyond on a single home device, aiming to promote a comprehensive understanding of users’ bodies and health conditions akin to a thermometer’s role. Inito asserts the global availability of its products, with users having reported more than 10,000 pregnancies and conducted over 2.5 million tests. The company is eagerly anticipating seizing the extensive opportunities within the $100 billion diagnostic testing market.
Inito-Funding and Acquisition
According to Crunchbase, the Inito start-up has to date raised a sum of $13M from a total of six investors in seven funding rounds. The lead investors include -Fireside Ventures, Z21Ventures, and the Y Combinator. In October 2022, Fireside, a venture capital firm focused on early-stage consumer ventures, declared the successful completion of its third fund, securing a total of $225 million.
Subsequently, on November 15, 2023, Fireside Ventures made its most recent investment, injecting $6 million into a new venture. It is to be noted that Fireside Ventures is committed not only to financial support but also to valuable
mentorship and strategic guidance. There are not any acquisitions made by the start-up yet.
Key Competitors & Future Plans
Some key competitors of the Inito start-up include-Hormona, Proov, Kegg, Mira, Clear! Blue and others.
Inito plans to use fresh funds to expand its hormone test globally, focusing on AI-driven analytics and R&D for new tests. The company plans to scale its business operations, build an Android app, and invest in R&D for new products. The start-up is developing point-of-care tests for pregnancy health, ovarian reserve, and male fertility hormones, utilizing hardware, biotechnology, and machine learning to enhance accuracy and reliability. Inito, a startup, plans to utilize new funding to develop advanced analytics on the menstrual cycle, utilizing AI to analyze hormones and correlate symptoms, moods, sleep patterns, and medications.
